Towards the development of new subtype-specific muscarinic receptor radiopharmaceuticals — Radiosynthesis and ex vivo biodistribution of [18F]3-(4-(2-(2-(2-fluoroethoxy)ethoxy)ethylthio)-1,2,5-thiadiazol-3-yl)-1-methyl-1,2,5,6-tetrahydropyridine
BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE
申请人:Arvinas Operations, Inc.
公开号:US20190300521A1
公开(公告)日:2019-10-03
The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE
申请人:Arvinas, Inc.
公开号:US20180125821A1
公开(公告)日:2018-05-10
The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.
A synthetic method for oligo(ethyleneglycol) toward 44-mer (FW = 1956.35) is described. Reiteration of Williamson's ether synthesis and hydrogenation to remove protecting benzyl group affords desired oligo(ethyleneglycol) toward 44-mer in moderate yields. The advantages in this method are use of commercially easily available materials as starting materials and procedures avoiding difficulty in purification
Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1
作者:Andrew P. Crew、Kanak Raina、Hanqing Dong、Yimin Qian、Jing Wang、Dominico Vigil、Yevgeniy V. Serebrenik、Brian D. Hamman、Alicia Morgan、Caterina Ferraro、Kam Siu、Taavi K. Neklesa、James D. Winkler、Kevin G. Coleman、Craig M. Crews
DOI:10.1021/acs.jmedchem.7b00635
日期:2018.1.25
process for identifying degrader hits based on the serine/threonine kinase TANK-binding kinase 1 (TBK1) and have generalized the key structural elements associated with degradation activities. Compound 3i is a potent hit (TBK1 DC50 = 12 nM, Dmax = 96%) with excellent selectivity against a related kinase IKKε, which was further used as a chemical tool to assess TBK1 as a target in mutant K-Ras cancer
靶向嵌合体的蛋白水解(PROTAC)是双功能分子,可将E3连接酶募集至目标蛋白质,以促进该蛋白质的泛素化和随后的降解。虽然靶向降解剂的领域还比较年轻,但这种方法成为分化和治疗现实的潜力很强,因此学术机构和制药机构现在都在进入这一有趣的研究领域。在本文中,我们描述了一种基于丝氨酸/苏氨酸激酶TANK结合激酶1(TBK1)识别降解子命中点的广泛适用的过程,并概括了与降解活动相关的关键结构要素。化合物3i命中率很高(TBK1 DC 50 = 12 nM,D max (= 96%)对相关激酶IKKε具有优异的选择性,该激酶还被用作化学工具,以评估TBK1作为突变K-Ras癌细胞中的靶标。
Silver(I) oxide-mediated facile and practical sulfonylation of alcohols
Primary and secondary alcohols were efficiently sulfonylated in the presence of silver(I) oxide and potassium iodide in dichloromethane. The sulfonylation occurs under mild, neutral reaction conditions. The ease of isolation of the final product presents a marked advantage over the known methodologies.